Literature DB >> 32008627

The Biology of Lung Cancer: Development of More Effective Methods for Prevention, Diagnosis, and Treatment.

Ramin Salehi-Rad1, Rui Li2, Manash K Paul2, Steven M Dubinett3, Bin Liu4.   

Abstract

Lung cancer is a heterogeneous disease with abundant genomic alterations. Chronic dysregulated airway inflammation facilitates lung tumorigenesis. In contrast, antitumor host immune responses apply continuous selective pressure on the tumor cells during the evolutionary course of the disease. Unprecedented advances in integrative genomic, epigenomic, and cellular profiling of lung cancer and the tumor microenvironment are enhancing the understanding of pulmonary tumorigenesis. This understanding in turn has led to advancements in lung cancer prevention and early detection strategies, and the development of effective targeted therapies and immunotherapies with survival benefit in selected patients.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biology of lung cancer; Genomic alterations; Immunotherapy; Lung cancer early detection; Lung cancer prevention; NSCLC and SCLC; Targeted therapy; Tumor microenvironment

Mesh:

Year:  2020        PMID: 32008627     DOI: 10.1016/j.ccm.2019.10.003

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  8 in total

1.  Canonical NF-κB Promotes Lung Epithelial Cell Tumour Growth by Downregulating the Metastasis Suppressor CD82 and Enhancing Epithelial-to-Mesenchymal Cell Transition.

Authors:  Eugenia Roupakia; Evangelia Chavdoula; Georgia Karpathiou; Giannis Vatsellas; Dimitrios Chatzopoulos; Angeliki Mela; Jennifer M Gillette; Katharina Kriegsmann; Mark Kriegsmann; Anna Batistatou; Anna Goussia; Kenneth B Marcu; Emmanouil Karteris; Apostolos Klinakis; Evangelos Kolettas
Journal:  Cancers (Basel)       Date:  2021-08-26       Impact factor: 6.575

2.  Survival Trends After Surgery for Spinal Metastatic Tumors: 20-Year Cancer Center Experience.

Authors:  Robert J Rothrock; Ori Barzilai; Anne S Reiner; Eric Lis; Adam M Schmitt; Daniel S Higginson; Yoshiya Yamada; Mark H Bilsky; Ilya Laufer
Journal:  Neurosurgery       Date:  2021-01-13       Impact factor: 4.654

3.  Leukotriene B4 receptor-2 contributes to KRAS-driven lung tumor formation by promoting interleukin-6-mediated inflammation.

Authors:  Jae-Hyun Jang; Donghwan Park; Guen-Soo Park; Dong-Wook Kwak; JaeIn Park; Dae-Yeul Yu; Hye Jin You; Jae-Hong Kim
Journal:  Exp Mol Med       Date:  2021-10-11       Impact factor: 8.718

4.  Prediction of lung cancer using gene expression and deep learning with KL divergence gene selection.

Authors:  Suli Liu; Wu Yao
Journal:  BMC Bioinformatics       Date:  2022-05-12       Impact factor: 3.307

5.  Predictive value of baseline metabolic tumor volume for non-small-cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.

Authors:  Ke Zhu; Danqian Su; Jianing Wang; Zhouen Cheng; Yiqiao Chin; Luyin Chen; Chingtin Chan; Rongcai Zhang; Tianyu Gao; Xiaosong Ben; Chunxia Jing
Journal:  Front Oncol       Date:  2022-09-06       Impact factor: 5.738

Review 6.  Lung cancer in never smokers: Tumor immunology and challenges for immunotherapy.

Authors:  Viviane Teixeira L de Alencar; Amanda B Figueiredo; Marcelo Corassa; Kenneth J Gollob; Vladmir C Cordeiro de Lima
Journal:  Front Immunol       Date:  2022-08-24       Impact factor: 8.786

7.  Tempol differently affects cellular redox changes and antioxidant enzymes in various lung-related cells.

Authors:  Woo Hyun Park
Journal:  Sci Rep       Date:  2021-07-21       Impact factor: 4.379

8.  BUB1B (BUB1 Mitotic Checkpoint Serine/Threonine Kinase B) promotes lung adenocarcinoma by interacting with Zinc Finger Protein ZNF143 and regulating glycolysis.

Authors:  Xiaolei Zhou; Yanli Yuan; Hongping Kuang; Bingxiang Tang; Hui Zhang; Manlin Zhang
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.